Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
about
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerShort-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trialMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer5α-Reductase inhibitors and risk of high-grade or lethal prostate cancerA tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).Prevention and early detection of prostate cancer.The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesActive surveillance for the management of localized prostate cancer: Guideline recommendationsObservation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.Active surveillance for low-risk prostate cancer.The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.Current status of 5α-reductase inhibitors in prostate disease managementDoubly blind: a systematic review of gender in randomised controlled trials.Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerThe Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancerThe intriguing role of fibroblasts and c-Jun in the chemopreventive and therapeutic effect of finasteride on xenograft models of prostate cancer.Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancerProstate cancer screening and the management of clinically localized disease.Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implicationsActive surveillance for prostate cancer: overview and update.Advances in prostate cancer chemoprevention: a translational perspective.Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.Evidence for compliance with long-term medication: a systematic review of randomised controlled trials.Expectant management for men with early stage prostate cancer.Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.Prostate Cancer Prevention: Concepts and Clinical Trials.Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.Androgen Signaling in Prostate Cancer.Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer.5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study.5-ARI use in active surveillance: Different paradigm than primary prevention but caution still needed.MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.Grade-dependent Response to Finasteride in Early Prostate Cancer.Testosterone therapy and prostate cancer--safety concerns are well founded.Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
P2860
Q26750620-45CB8EDC-EDAB-4F73-BEE7-E09DBA593B0AQ27009177-AF767C9B-9CB9-4C58-879F-8C23FC0BA104Q27024775-268F85BA-9E2E-4AA3-9975-2F91D8003D8FQ34005866-2FC07257-FA8D-424A-A182-7E4F58E4CAA3Q34141355-2A086010-6486-48CF-A3DA-5928AABF4705Q34371057-08720F17-499E-4606-8130-73D4915785A7Q34531624-B2A30085-8EF5-485C-A1FE-A30E23293FF0Q35213928-AAEB44B5-5379-44F1-B509-751880C9C913Q35498903-6AFF6092-B5AD-40EC-9C2B-3851EC20F9A2Q35569303-79571A93-1532-435E-A110-6CEA35992E4CQ35725546-EA750E1E-6859-4058-89AA-B01FCF6A4B98Q35806400-68B4FD85-0159-4466-A635-A7F8B7014DC0Q36141777-16968F9C-1BA8-4020-A004-647625DF9470Q36728894-BA424898-109B-45E5-8CDC-CA69BF83A2F8Q36778346-29393007-C4EF-40C0-BFE5-60E32ED9603BQ36805845-DBD82DA1-D571-476A-93F1-70D124B974F8Q36937301-E21C234B-9DE9-4D3E-B1FE-FCB7C495B197Q37009071-640BC6C1-3464-49AF-AAB8-86130B666CDCQ37260055-BBE4B610-AD3A-4385-9DAD-C21458AE8D04Q37414987-2D7B8F93-CBC4-4656-B319-6852CEAA7FF6Q37421848-85D8A6D9-B26D-4B3A-B266-EA1E16464D91Q37609671-8E431383-FDD3-466C-A9E6-5257A6E6C6FAQ37639218-FACE6F90-9165-4CD2-A8AB-070720FE1C2EQ38074079-21DE54EF-0B82-4737-B4F2-2F04A0F5D5F8Q38107513-67BC5837-3D39-42F3-A171-3073A5AF0807Q38118357-99B6E004-DFE2-448D-B5EA-65526956573DQ38167704-7272356E-3019-4AC4-B80E-7191108E6D7BQ38469754-84FA42C8-6F5F-4D64-960B-A7D315BD9AE9Q38733910-A7E61491-FCFD-4A12-86E8-3BF8626796A4Q38766396-246FE5B1-4CDE-459B-BAF4-8A1DAD6D7209Q38823187-04642E92-B168-4438-BDC4-F2D5B9751AC2Q39227656-FF441327-B6F4-4EB2-82A4-D3BB285474B7Q39380290-55B45476-5284-4ADA-BDAF-6FC1633626B1Q41250210-D5311500-EEBF-4489-9762-1B0CD5CFCB65Q41338878-815731AE-8036-48E6-8223-F2F0E2E8CC0EQ42115694-20E6B2D9-F417-4E84-A602-9B33D75F413CQ42374251-96E6E51E-A3E5-44DF-A927-5A70BFBBBC73Q42705135-456E2587-D97D-4A2D-B8EB-9871E3B7DAC8Q43594011-3682054D-AF45-45C3-8DB6-FA5B482F5AAAQ46907494-781B7B8F-545C-44E3-9238-71FE3CF649CE
P2860
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@en
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@nl
type
label
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@en
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@nl
prefLabel
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@en
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@nl
P2093
P1433
P1476
Dutasteride in localised prost ...... ind, placebo-controlled trial.
@en
P2093
Blair Egerdie
Gregg Eure
Indrani Nandy
Libby Black
Lorne Aaron
M Scott Lucia
Neil E Fleshner
Roger S Rittmaster
P304
P356
10.1016/S0140-6736(11)61619-X
P407
P577
2012-01-24T00:00:00Z